Uncategorized

BioMarin acquires experimental drug for rare bone disorder in $275M deal

Published

on

The Alesta buyout helps restock BioMarin’s pipeline with an asset it says could “reach our largest addressable patient population,” joining other muscle and skeletal disease treatments in development.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version